The population bioresources and genomics grouping of CVDM is a world leading team investigating the genetic basis for susceptibility to, and treatment of diabetes and cardiovascular diseases. This grouping has pioneered the linkages of genomics to the electronic medical record in collaboration with the Health Informatics Centre (now part of the Farr Institute).
This has resulted in the recruitment of over 40,000 members of the Tayside population being recruited into genetic studies. These studies are collectively managed as the Tayside Bioresource(link). The GoDARTS (Morris, Palmer, Pearson, Doney) study is one of the largest case/control studies of type 2 diabetes in the world and has been a key contributor to the ongoing discovery of over 80 genes for type 2 diabetes (link to refs). GoDARTS is also a major pioneering study in the use of Electronic Medical Records to elucidate the genetics of diabetes complications including cardiovascular outcomes (Palmer, Doney) and response to therapy (Palmer, Pearson). This has been recently complemented by the hosting of the Scottish wide Type 1 diabetes Bioresource which has recruited over 6000 cases of type 1 diabetes for genetic and biomarker research
Research into Cardiovascular disease includes the TASCFORCE study (Belch, Struthers) where early predictors of heart disease are being established and BIOSTAT-CHF looking at predictors of susceptibility to heart failure and the effectiveness of current therapies (Lang). In respiratory biology studies of COPD (GoTARDIS) and asthma (BREATHE) are seeking to improve the treatment of these diseases through the discovery of genetic markers for drug response (Lipworth, Palmer, Schembri, Chambers). A major focus has been on the use of genetics to personalize the use of long-acting beta agonists and inhaled steroids.
The genomics grouping has recently established the pre-consent of the population to the use of spare blood in genomic research (GoSHARE). In collaboration with the Scottish Primary Care Research Network and NHS Tayside Blood Sciences, we have automated the interception of preconsented bloods form routine NHS laboratory testing. Pilot data has shown that 75% of consented adults will have a suitable blood test over a three year period. This will be a major resource in the search for markers to personalize the treatment of a wide range of diseases including diabetes and cardiovascular disease.